Stephen Walsh, MD
Adult Reconstructive Orthopaedic Surgery · Bangor, MENPI 1386690501
Payments from drug & device makers
What this record shows
This record is dominated by other: $736,587 of the $744,743 with a category attached, or 98.9%. Zimmer Biomet accounts for 99.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $737,287 and has fallen 99.6% since, to $2,945 in 2025.
Across 66 payments — averaging $11,284 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$744K
- Stryker$388
- Encore Medical, LP$168
- Smith+Nephew$37
- Endo Pharmaceuticals Inc.$25
- Pacira Pharmaceuticals Incorporated$16
What the payments were for
- Travel & lodging$3,6840%
- Food & beverage$3,7481%
- Education$7240%
- Other$736,58799%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 55 | $744,109 |
| Stryker | 5 | $388 |
| Encore Medical, LP | 3 | $168 |
| Smith+Nephew | 1 | $37 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Low Profile Reamer$736,587
- Arcos$1,465
- Oxford$1,441
- Persona$1,104
- ROSA$396
- Persona Revision$214
- Hips-None$194
- RIO$141
How this compares
Too few adult reconstructive orthopaedic surgery providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 63 | $2,171 |
| Famotidine | 62 | $527 |
| Tramadol Hcl | 121 | $436 |
| Dexamethasone | 86 | $358 |
| Methocarbamol | 30 | $127 |
| Oxycodone Hcl | 11 | $83 |
| Meloxicam | 12 | $83 |
| Amoxicillin | 34 | $36 |
Paid to pharmacies, not to this prescriber.
Other adult reconstructive orthopaedic surgery in Bangor
- Megan RichardsBangor$4K
- Jason BourqueBangor$23
- Brian McGroryFalmouth$424K
- Michael RobertsFalmouth$56K
- Joseph YoungFalmouth$16K
- Zafar AhmadLewiston$14K
- Justin KuetherFalmouth$10K
- Michael DefranceAuburn$8K
- Brigham McKenneySouth Portland$3K
- Donald EndrizziFalmouth$107
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.